On the afternoon of May 27, jointly organized by the Embassy of the Netherlands, the Netherlands Foreign Investment Agency (NFIA) and 3EACON Inc., Seminar on Balancing Regulation and Innovation (hereafter refer to as “Seminar”) was successfully held in Beijing. Experts and representatives from drug regulatory agencies, clinical research institutions and pharmaceutical industry in China and Netherlands were invited to carry on in-depth discussions on the EU drug regulation, innovation, scientific development. More than 60 representatives from members of China Pharmaceutical Innovation and Research Development Association (hereinafter referred to as the “PhIRDA”) and pharmaceutical industry in China and Netherlands participated in this event.

Mr. Bas Pulles, Deputy Head of Mission, Embassy of the Netherlands in China, delivered the opening speech. After a warm welcome, Mr. Bas Pulles introduced the cooperative fruits in multiple fields including economy and trade, healthcare, scientific and technological innovation and education between China and the Netherlands, and expressed full confidence for further bilateral cooperation in life science and pharmaceutical innovation industry. In his speech, he mentioned that in March 2019, European Medicine Agency (EMA) moved from London to Amsterdam of the Netherlands, as an EU member and a host country, the Netherlands has been involving actively in EMA working group and platform building to provide solid support and foundation for EMA’s work after relocation.

Mr. Bas Pulles, Deputy Head of Mission, Embassy of the Netherlands in China, delivered opening speech

Mr. Ton de Boer, Chairman of Medicines Evaluation Board, the Netherlands, Joop van Gerven, Chairman Central Committee on Research Involving Human Subjects, and Wolf Ondracek, Board Member Entrepreneurs Association Leiden Bio Science Park; Co-founder & Partner 3EACON representatively made keynote speeches on how the moving of EMA could affect European drug regulation, innovation and scientific research development under Briexit, and introduced the development of clinical trials and life science in the Netherlands. Experts and representatives had a heated discussion on drug regulation, market access, genetic diagnosis, racial differences in clinical data and so forth.

Mr. Ton de Boer, Chairman Medicines Evaluation Board, made keynote speech

Mr. Joop van Gerven, Chairman Central Committee on Research Involving Human Subjects, made keynote speech 

Mr. Wolf Ondracek, Board Member Entrepreneurs Association Leiden Bio Science Park; Co-founder & Partner 3EACON, made keynote speech

Centering on the principle of “innovation, industrialization and internationalization”, PhIRDA has been always committed to promoting pharmaceutical innovation in China, and keeping a long-term close cooperation with the Dutch pharmaceutical community. In June this year, to promote further cooperation on drug R&D between China and the Netherlands, PhIRDA Delegation will visit the Netherland to learn the encouraging drug innovation policy, pharmaceutical market and investment climate, seeking for high-quality pharmaceutical innovative projects.

The seminar provided a communication platform for pharmaceutical innovation and drug R&D between the Netherland and China. Representatives exchanged profound views on drug innovation and regulation, laying a solid foundation for bilateral cooperation. LU Xiaoti, Deputy Secretary-General of PhIRDA, RUAN Xinxin, Deputy Director of International Affairs and LI Gen, Project Assistant of International Affairs attended the seminar.

Plenary Meeting